Compare WOLF & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOLF | EVO |
|---|---|---|
| Founded | 1987 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4766 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 505.2M | 895.8M |
| IPO Year | 2025 | N/A |
| Metric | WOLF | EVO |
|---|---|---|
| Price | $14.88 | $2.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $12.75 | $7.00 |
| AVG Volume (30 Days) | ★ 1.4M | 110.9K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,385,982,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.43 | $7.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $0.39 | $2.31 |
| 52 Week High | $36.60 | $4.80 |
| Indicator | WOLF | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 39.09 | 33.27 |
| Support Level | $13.49 | $2.31 |
| Resistance Level | $19.05 | $3.75 |
| Average True Range (ATR) | 1.26 | 0.08 |
| MACD | -0.23 | 0.02 |
| Stochastic Oscillator | 0.97 | 27.48 |
Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.